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Introduction: Cobalt ions (Co2+) stabilize HIFα and increase endogenous erythropoietin
(EPO) production creating the possibility that Co2+ supplements (CoSupp) may be
used as performance enhancing substances. The aim of this study was to determine
the effects of a small oral dosage of CoSupp on hemoglobin mass (Hbmass) and
performance with the objective of providing the basis for establishing upper threshold
limits of urine [Co2+] to detect CoSupp misuse in sport.
Methods: Twenty-four male subjects participated in a double-blind placebo-controlled
study. Sixteen received an oral dose of 5mg of ionized Co2+ per day for 3 weeks,
and eight served as controls. Blood and urine samples were taken before the study,
during the study and up to 3 weeks after CoSupp. Hbmass was determined by the
CO-rebreathing method at regular time intervals, and VO2max was determined before
and after the CoSupp administration period.
Results: In the Co2+ group, Hbmass increased by 2.0 ± 2.1% (p < 0.001) while all
the other analyzed hematological parameters did not show significant interactions of
time and treatment. Hemoglobin concentration ([Hb]) and hematocrit (Hct) tended to
increase (p = 0.16, p = 0.1) and also [EPO] showed a similar trend (baseline: 9.5 ± 3.0,
after 2 weeks: 12.4 ± 5.2 mU/ml). While mean VO2max did not change, there was a
trend for a positive relationship between changes in Hbmass and changes in VO2max
immediately after CoSupp (r = 0.40, p = 0.11). Urine [Co2+] increased from 0.4 ± 0.3 to
471.4 ± 384.1 ng/ml (p < 0.01) and remained significantly elevated until 2 weeks after
cessation.
Conclusion: An oral Co2+ dosage of 5 mg/day for 3 weeks effectively increases
Hbmass with a tendency to increase hemoglobin concentration ([Hb]) and hematocrit
(Hct). Because urine Co2+ concentration remains increased for 2 weeks after cessation,
upper limit threshold values for monitoring CoSupp can be established.
Keywords: erythropoietin, aerobic performance, doping, blood manipulation, supplement, sports nutrition
Hoffmeister et al. Low-Dose Cobalt and Hemoglobin Mass
INTRODUCTION
From the mid-1940s until the 1980s, cobalt ions (Co2+) were
used for patients experiencing anemia from various causes
(Jelkmann, 2012; Ebert and Jelkmann, 2014). Co2+ acts similarly
as a hypoxic stimulus; it stabilizes HIF-1α and HIF-2α and
thereby increases plasma erythropoietin concentration ([EPO]
(for a review, see Jelkmann, 2012). Because of the severe side
effects of high-dose Co2+ treatment, it was replaced by anabolic
steroids and later by recombinant erythropoietin (Ebert and
Jelkmann, 2014).
Maximum oxygen uptake as a measure of endurance
performance is closely related to the absolute amount of
circulating hemoglobin. After phlebotomy or after application
of rhEPO, a change of 1 g of hemoglobin causes a change in
VO2max of approx. 4 ml/min (Schmidt and Prommer, 2010).
This is why blood manipulation, either by erythropoietic agents
or by blood transfusions, occurs widely as a malpractice within
elite endurance sports (Sottas et al., 2011; Wintermantel et al.,
2016). CoSupp could also be used to stimulate endogenous
EPO production and to increase endurance performance
(Lippi et al., 2005, 2006). In recent years, CoSupp has been
marketed as a nutritional supplement for endurance athletes
with unsubstantiated performance enhancing effects (Thevis
et al., 2016). It is therefore no surprise that CoSupp has been
discussed among athletes, and in 2015, World Anti-Doping
Agency (WADA) included CoSupp in its prohibited list (WADA,
2017). Until now, however, no threshold values for urine or blood
indicating CoSupp use have been established.
Because small amounts of Co2+(∼0.1 µg/day) are an essential
co-factor for vitamin B12 (Tvermoes et al., 2013, 2014), Co2+ is
a necessary component of our daily nutrition. Co2+ is detectable
in blood (Tvermoes et al., 2014) and urine (Krug et al., 2014),
but the concentrations are very low and close to the detection
limits. To create upper threshold limits in blood and urine
for the detection of CoSupp misuse, the amount necessary for
erythropoietic stimulation must be known. For this purpose,
earlier studies are not helpful, as they used very high dosages
(mostly > 25mg Co2+/day) (Bradberry et al., 1989; Finley et al.,
2012), which increase the risk of acute poisoning and organ
injury, such as gastrointestinal sickness, thyroid dysfunction,
myocardial effects and neural disturbances (Ebert and Jelkmann,
2014). Studies using low-dose oral CoCl2 in healthy volunteers
at 0.45mg Co2+/day for 2 weeks (Tvermoes et al., 2013) and
1mg Co2+/day for 90 days (Tvermoes et al., 2014) did not yield
hematological changes, with the exception of a decrease in ferritin
during the 90-day period.
In a recent study, the minimum amount of daily oral
Co2+ administration leading to increased plasma [EPO] was
determined (Hoffmeister et al., 2018). A single dosage of 10mg
in moderately trained young men resulted in a 53% increase
in [EPO], and a dosage of 10mg for 5 days resulted in
a 50% increase in immature reticulocyte fraction and 12%
decrease in ferritin concentration. A dosage of 5mg Co2+
increased plasma [EPO] by 20% which can be assumed to
be closer to the erythropoietic threshold than 10mg per day.
Long-term administration of this dosage may be effective
for increasing hemoglobin mass and improving endurance
performance.
The aim of this study was to administer a 3-week daily 5mg
Co2+ treatment to healthy leisure athletes and investigate the
effects on hemoglobin mass and aerobic performance.
METHODS
Subjects
In total, 24 healthy male non-smoking subjects participated in
the study. Eight received a placebo and 16 received the Co2+
supplement. The subjects were recruited by a notice shown to
sports students at the University of Bayreuth. The project was
approved by the ethics committee of the University of Bayreuth,
Germany. All subjects were informed in verbal and written form
about the aim of the study, the possible risks, and the possibility
to withdraw without any personal consequences, and they gave
their written informed consent. The anthropometric data of the
test subjects are presented in Table 1.
Design of the Study
The study was performed using a double blind, placebo-
controlled design consisting of a 1-week baseline period, a
3-week supplementation period and a 3-week post-treatment
period. Sixteen subjects received a daily oral dosage of CoSupp
containing 5mg Co2+, and eight of the subjects received a
placebo.
Venous blood and urine samples were taken before (duplicate
measures) during (once per week) and after (immediately and
once per week for 3 weeks) the treatment. Each blood sample
included 3ml for whole blood parameters and 9ml for serum
parameters while urine samples consisted of 50ml collected in
the morning.
Hemoglobin mass (Hbmass) was determined before
(duplicate measures), during and after the treatment period.
An aerobic performance test (incremental step test) on a cycle
ergometer was performed before, the day after and 1 week after
the treatment period.
Cobalt Supplementation
A commercially available dietary CoSupp (Minerallife©,
Colorado Springs, CO, USA) was used after its Co2+ content was
checked in theWADA-accredited Institute of Biochemistry of the
German Sport University, Cologne, Germany. Besides ionized
cobalt (Co2+) listed additional ingredients were carbohydrate
derived fulvic acid, natamycin, and nisin which were included
for their anti-bacterial and anti-fungal properties.
The real Co2+ concentration of the liquid supplement
markedly deviated from the data provided by the manufacturer
(0.2 mg/ml) and ranged between 0.24 and 0.86 mg/ml in different
batches. The amount of Co2+ administered to our subjects was,
therefore, calculated from our own results and not from the
manufacturer’s information. The subjects received their CoSupp
in a mixture of orange juice and buttermilk partitioned in five
doses every 4 h (except in the morning at 4 am) for 3 weeks.
The eight control subjects received a placebo, orange juice with
buttermilk, at the identical times. All subjects were regularly
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TABLE 1 | Anthropometric characteristics of the test subjects.
n = Age (years) Height (cm) Body mass (kg) BMI
Placebo 8 22.4 ± 2.0 181.1 ± 5.1 77.7 ± 5.1 23.7 ± 1.4
Cobalt 16 22.9 ± 2.6 179.9 ± 6.2 75.0 ± 8.8 23.1 ± 2.0
questioned as to whether they were experiencing any side effect.
No subject reported any side effect during and for 3 weeks after
the treatment.
Sample Transport and Storage
The whole procedure, including urine collection, blood sampling,
sample transport, sample storage and sample analyses, was
performed according to current WADA guidelines (WADA,
2016). The blood samples were taken in the morning between
8 and 9 a.m. after leaving the subject for at least 15min in a
sitting position. Within 24 h, the samples were transported under
monitored cool conditions to the WADA-accredited Institute of
Doping Analysis and Sports Biochemistry in Dresden, Germany.
Urine samples were taken 15–20min before blood sampling,
and an aliquot of 50ml was also transported under the same
standardized conditions to the Institute of Biochemistry of the
German Sport University, Cologne, Germany, where samples
were stored at−80◦C until they were analyzed.
Urine and Blood Analytical Procedures
For cobalt ion analysis, urine samples were subjected to an
EN ISO 17294-accredited test method for the quantitative
determination of cobalt in an aqueous and urinary matrix
using inductively coupled plasma-mass spectrometry (ICP-MS).
In brief, urine aliquots were diluted with aqueous HNO3
and subjected to ICP-MS analysis using a Thermo (Bremen,
Germany) Element 2 magnetic sector or XSERIES 2 apparatus.
The method’s limit of quantification (LOQ) was 0.5 ng/mL (see
Krug et al., 2014).
The Sysmex XT2000i hematological analyzer (Sysmex,
Norderstedt, Germany) was used for the determination of
hemoglobin concentration ([Hb]), hematocrit (Hct), reticulocyte
number, immature reticulocyte fraction (IRF), red cell indices
and other routine hematological parameters.
In serum, the following parameters were determined:
ferritin [LKFE1, ELISA & Immulite 1000 (Siemens Healthcare
Diagnostics GmbH, Germany)], erythropoietin (EPO) [LKEP1,
ELISA & Immulite 1000 (Siemens Healthcare Diagnostics
GmbH, Germany)], soluble transferrin receptor (sTFR)
[Quantikine IVD (DTFTR1) Assay (R&D Systems, bio-techne,
Wiesbaden, Germany) & Infinite 200 PRO (Tecan, Switzerland)],
and C-reactive protein (CRP) [high sensitive–LKCRP1, ELISA
& Immulite 1,000 (Siemens Healthcare Diagnostics GmbH,
Germany)].
Hemoglobin Mass Determination
Hemoglobin mass was determined by using the optimized CO-
rebreathing method as described and modified by Schmidt
and Prommer (Schmidt and Prommer, 2005; Prommer and
Schmidt, 2007). Briefly, a bolus of 99.97% carbonmonoxide (CO;
1.0ml CO per kg body mass) was administered to subjects and
rebreathed along with 3 liters of 100% O2 for 2min. Arterialized
capillary blood samples were taken from a hyperemized earlobe
before and 7min after the rebreathing procedure and analyzed
in sextuplicate using an OSM3 hemoximeter (Radiometer,
Denmark). End tidal [CO] was assessed before and 2min after
the rebreathing procedure using a portable CO detector (Draeger
Pac7000, Germany). Hbmass was assessed in duplicate prior to
the intervention; there was no significant difference between the
2 baseline tests (difference: 7.4 ± 19.5 g, n = 24) so the mean of
each subject’s 2 tests was used as their baseline value. Typical error
for Hbmass determined from these duplicate measurements
was 1.6%.
Aerobic Performance Determination
Aerobic performance was determined on a cycle ergometer
(Lode, Groningen, Netherlands) by starting with 100 watts
(3min) and increasing the load by 50 watts every 3min (this
occurred stepwise every minute by steps of 17, 17, and 16
Watts) until subjective exhaustion. Key dependent variables were
VO2max (METALYZER
R© 3B, Cortex, Leipzig Germany), time
until exhaustion, power at exhaustion, and sub-maximal power
at blood lactic acid concentrations of 2 mmol/l and 4 mmol/l.
Blood samples for lactic acid determination were taken from a
hyperemized earlobe before exercise, every 3min during exercise
plus immediately and 1, 3, 5, and 7min after exhaustion. The
typical error for determination of VO2max in our laboratory
is 2.5%.
Statistics
Data are presented as the mean ± standard deviation (SD). An
analysis of variance with repeated measurements was carried
out to detect main effects for group and time as well as group
by time interactions. Significance level was set at p < 0.05. In
case of significant outcome of the ANOVA (interaction of time
and treatment), unpaired t-tests were used to compare mean
values for both groups at identical time points, and paired t-tests
were used to compare the mean values of identical individuals at
different time points. Linear regression analyses were performed
to detect any relationship between VO2max and Hbmass.
RESULTS
Cobalt Excretion in Urine
Urine cobalt concentration (Figure 1) was elevated with
CoSupp during the 3-week Co2+ application period. Mean
values of 305 ± 209 ng/ml (significance against baseline:
p < 0.01) were found after week 1 and significantly
increased to 456 ± 402 ng/ml (p < 0.01) by the end of
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FIGURE 1 | Urine cobalt concentration during and until 3 weeks after the 3-week Co2+ administration period. Significant changes from baseline values: *p < 0.05,
**p < 0.01.
FIGURE 2 | Changes in hemoglobin mass during and after the 3-week cobalt application period. Significant changes from baseline values: *, **, ***p < 0.05, 0.01,
0.001; between groups: #p < 0.05. The dashed line indicates the difference between cobalt and placebo groups.
week 3. During the post-treatment period values decreased
over time but did not return to baseline until 2 weeks
after the treatment. It should be noted that there was a
large intra- (mean STD = 172 ng/ml) and inter- (mean
STD = 254 ng/ml) subject variability in urine cobalt
concentration.
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TABLE 2 | Changes in serum EPO, TfR, ferritin, and CRP concentrations between the cobalt vs. placebo groups before, during, and after cobalt administration.
Cobalt administration Post-administration period
Baseline 7 days 14 days 21 days 2 days 7 days 14 days 21 days
EPO (mIU/ml) Cobalt 9.5 ± 3.0 10.1 ± 2.9 12.4 ± 5.2 10.6 ± 3.5 10.8 ± 4.4 10.9 ± 6.2 12.6 ± 4.5 11.6 ± 4.1
Placebo 9.8 ± 1.7 9.6 ± 2.0 10.2 ± 2.7 11.3 ± 2.8 10.2 ± 3.2 10.3 ± 3.0 10.2 ± 3.3 14.5 ± 4.2
sTfR (nmol/l) Cobalt 27.8 ± 5.2 28.1 ± 6.6 31.7 ± 6.0 29.8 ± 4.8 30.9 ± 6.9 30.5 ± 6.3 30.9 ± 5.5 29.5 ± 9.5
Placebo 33.4 ± 4.6 32.7 ± 3.6 33.6 ± 6.2 31.6 ± 5.2 33.5 ± 7.4 35.8 ± 8.5 29.9 ± 8.5 32.8 ± 5.6
Ferritin (ng/ml) Cobalt 108 ± 46 94 ± 42* 92 ± 40* 89 ± 46** 88 ± 42** 89 ± 44* 94 ± 37* 98 ± 47
Placebo 108 ± 49 93 ± 53* 95 ± 51 100 ± 43 92 ± 38 92 ± 38 108 ± 42 97 ± 57
CRP (mg/l) Cobalt 2.6 ± 4.9 1.4 ± 1.8 2.0 ± 2.3 1.5 ± 2.4 1.2 ± 1.7 2.1 ± 4.8 3.4 ± 6.4 2.6 ± 3.5
Placebo 0.6 ± 0.3 1.1 ± 1.1 0.8 ± 0.5 0.6 ± 0.7 0.5 ± 0.4 0.4 ± 0.3 0.8 ± 1.1 0.6 ± 0.3
Presented are means ± standard deviations (SD). EPO, erythropoietin; sTfR, serum transferrin receptor, and CRP, C-reactive protein. Significance of differences from baseline (post-hoc
tests): *, **p < 0.05, 0.01.
Changes in Hematological Parameters
The comparison of Hbmass of the cobalt and placebo groups
yielded a significant treatment by time interaction (p< 0.05). For
the cobalt group, post-hoc tests showed significant increases in
Hbmass from the first week of treatment until 1 week thereafter
(Figure 2).
Ferritin showed a clear time effect with decreasing
concentrations in both groups without an interaction of
time and treatment (Table 2).
All of the other parameters were not significantly affected by
CoSupp as indicated by non-significant interaction of time and
treatment. There were, however, trends in the cobalt group for
increased [Hb] (p= 0.16) andHct (p= 0.10;Table 3). Also [EPO]
tended to be higher after 2 weeks of CoSupp.
Performance
VO2max did not show any changes (Figure 3), while maximum
power and time until exhaustion increased over time (p < 0.05)
without a significant interaction between time and treatment
(Table 4). Sub-maximal power at 2 mmol/l and 4 mmol/l
blood lactate concentration tended to be affected by CoSupp
(interaction between time and treatment: p = 0.16, p < 0.22;
Table 4).
DISCUSSION
The most important finding from this study was that CoSupp
significantly increased hemoglobinmass, but did not significantly
alter aerobic performance. The lack of significant change for the
other measured dependent values such as VO2max and [EPO]
may likely relate to a greater methodological error in measuring
these variables compared to Hbmass. However, the significant
change in Hbmass and the tendency for [Hb] and Hct to increase
indicates that cobalt supplementation does alter erythropoietic
activity.
Cobalt Supplements
Some dietary supplements are promoted as performance-
boosting nutrients, although their active ingredients may
not be completely declared. Recently, Thevis et al. analyzed
19 commercially available dietary supplements advertised as
endurance performance enhancers (Thevis et al., 2016). Eleven of
them contained up to 2.6mg Co2+/ml, which was only declared
in two of these supplements. The Co2+ concentration of the
supplement used in this study was declared to be 0.2 mg/ml.
However, in almost half of the units we used for supplementation,
the real concentration was more than 3 times higher. This
data suggests that these kinds of dietary supplements have
to be used with caution to avoid any side effects caused by
undeclared and/or falsely declared Co2+ content. In this study,
we did not observe any side effect during and after the 5mg
Co2+ administration period. Finley et al. (Finley et al., 2012)
determined that a safe life time oral dose (RfD) of cobalt was
0.03mg Co2+ per kg body mass per day (2.1mg per day for
a 70 kg subject). Since during the 3-week cobalt treatment our
subjects exceeded this value by 2–2.5-fold without any acute side
effects, short-term administration of cobalt in this dose appears
to be safe.
Cobalt Excretion in Urine
In 2015, cobalt was put on the WADA prohibited list
under “S2-Peptide Hormones, Growth Factors, Related
Substances, and Mimetics” (WADA, 2017). However, a
threshold limit for determining cobalt use by athletes
has not been established even though some anti-doping
laboratories already test urine samples for their cobalt
content.
For the current protocol, the urine Co2+ concentrations
reported during the 3-week treatment period are in accordance
with data from the literature (Krug et al., 2014) and our
own experience (Hoffmeister et al., 2018). Because most of
the ingested cobalt is not absorbed, and because excretion
via feces is the main route for elimination of ingested Co2+,
urinary excretion accounts for between 10 and 27% of ingested
Co2+ (Ayala-Fierro et al., 1999; Hoffmeister et al., 2018). The
relatively high inter-individual variation of urine Co2+ observed
in this study may therefore be attributable to differences in
gastrointestinal Co2+ absorption, while the intra-individual
variation in the morning urine samples may also be due to
different diuresis.
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TABLE 3 | Changes in hematological parameters between the cobalt vs. placebo groups before, during, and after cobalt administration.
Cobalt administration Post-administration period
Baseline 7 days 14 days 21 days 2 days 7 days 14 days 21 days
Hbmass (g) Cobalt 839 ± 106 851 ± 120* 857 ± 113** 856 ± 110***.# 854 ± 112** 838 ± 67
Placebo 884 ± 116 883 ± 123 888 ± 132 874 ± 124 880 ± 119 916 ± 136
[Hb] (g/100ml) Cobalt 15.1 ± 0.9 15.3 ± 1.0 15.0 ± 1.1 15.2 ± 1.3 15.0 ± 1.0 15.1 ± 1.0 14.7 ± 0.9 15.1 ± 0.9
Placebo 15.1 ± 0.9 14.9 ± 1.0 15.2 ± 0.8 14.9 ± 1.0 14.8 ± 0.8 15.0 ± 1.2 14.8 ± 1.0 14.9 ± 1.0
Hct (%) Cobalt 43.3 ± 2.3 44.3 ± 2.5 43.3 ± 3.0 43.8 ± 3.5 43.5 ± 2.6 43.8 ± 2.8 42.8 ± 2.6 43.5 ± 2.8
Placebo 44.1 ± 2.5 43.7 ± 2.5 44.1 ± 2.2 43.7 ± 2.7 43.0 ± 2.6 43.9 ± 3.5 43.0 ± 3.1 43.6 ± 3.10
RBC (106/µl) Cobalt 5.00 ± 0.30 5.07 ± 0.29 4.96 ± 0.30 5.03 ± 0.43 4.97 ± 0.39 5.01 ± 0.29 4.88 ± 0.37 4.97 ± 0.39
Placebo 4.95 ± 0.31 4.89 ± 0.34 4.97 ± 0.29 4.90 ± 0.38 4.84 ± 0.38 4.93 ± 0.39 4.85 ± 0.41 4.93 ± 0.31
MCV (fl) Cobalt 87.0 ± 4.6 87.6 ± 4.3 87.5 ± 4.4 87.4 ± 4.5 87.6 ± 4.2 87.6 ± 3.5 88.1 ± 3.2 87.7 ± 3.7
Placebo 89.2 ± 3.1 89.5 ± 2.9 88.8 ± 3.3 89.3 ± 3.6 88.9 ± 3.2 89.2 ± 3.9 89.1 ± 3.8 88.6 ± 2.8
MCH (pg) Cobalt 30.3 ± 1.5 30.2 ± 1.5 30.3 ± 1.6 30.2 ± 1.6 30.3 ± 1.5 30.3 ± 1.2 30.3 ± 1.2 30.4 ± 1.3
Placebo 30.5 ± 1.0 30.4 ± 1.0 30.5 ± 1.1 30.5 ± 1.1 30.5 ± 1.1 30.5 ± 1.2 30.6 ± 1.2 30.3 ± 1.1
MCHC (g/dl) Cobalt 34.9 ± 0.7 34.5 ± 0.6 34.6 ± 0.7 34.6 ± 0.7 34.5 ± 0.6 34.6 ± 0.6 34.4 ± 0.6 34.2 ± 0.3
Placebo 34.2 ± 0.4 34.0 ± 0.5 34.4 ± 0.4 34.2 ± 0.55 34.29 ± 0.33 34.2 ± 0.6 34.4 ± 0.5 34.2 ± 0.3
Ret% (%) Cobalt 1.16 ± 0.42 1.25 ± 0.32 1.19 ± 0.33 1.25 ± 0.41 1.22 ± 0.32 1.14 ± 0.34 1.06 ± 0.37 1.06 ± 0.39
Placebo 1.07 ± 0.15 1.11 ± 0.21 1.12 ± 0.28 1.10 ± 0.25 1.13 ± 0.27 1.08 ± 0.19 1.02 ± 0.19 0.93 ± 0.19
Ret# (106/µl) Cobalt 0.058 ± 0.022 0.063 ± 0.018 0.059 ± 0.018 0.063 ± 0.024 0.061 ± 0.018 0.058 ± 0.019 0.052 ± 0.020 0.054 ± 0.023
Placebo 0.053 ± 0.010 0.054 ± 0.011 0.056 ± 0.016 0.055 ± 0.014 0.055 ± 0.016 0.053 ± 0.013 0.049 ± 0.010 0.046 ± 0.010
OFF-Score Cobalt 87.4 ± 9.5 86.6 ± 10.1 85.4 ± 7.3 85.4 ± 10.2 84.7 ± 9.2 88.1 ± 11.3 86.5 ± 9.8 89.6 ± 8.4
Placebo 88.7 ± 6.6 85.7 ± 9.3 88.7 ± 6.1 86.6 ± 6.8 84.3 ± 6.8 87.8 ± 8.5 87.5 ± 9.6 91.1 ± 9.6
IRF (%) Cobalt 5.5 ± 1.6 6.1 ± 1.9 5.4 ± 1.6 6.1 ± 1.7 5.8 ± 2.7 5.0 ± 1.9 5.3 ± 1.7 4.5 ± 1.4
Placebo 4.9 ± 1.3 5.0 ± 2.2 5.6 ± 1.5 5.4 ± 2.5 5.3 ± 1.6 3.7 ± 1.5 4.0 ± 1.3 4.6 ± 1.4
RDW-SD Cobalt 39.4 ± 2.3 40.2 ± 2.2 39.7 ± 2.3 39.8 ± 2.0 40.0 ± 2.0 39.7 ± 1.6 39.8 ± 1.2 39.7 ± 1.1
Placebo 40.5 ± 1.6 40.7 ± 1.6 39.9 ± 1.6 40.5 ± 1.8 39.8 ± 1.5 40.1 ± 2.4 39.8 ± 2.1 40.3 ± 1.8
Presented are means ± standard deviations (SD). MCV, mean erythrocyte volume; MCH, mean erythrocyte hemoglobin content; MCHC, mean hemoglobin concentration; Ret%,
reticulocyte percentage; Ret#, reticulocyte number; Off-score, ([Hb] (g/L)−60) × √ (reticulocyte percentage); IRF, immature reticulocyte fraction; RDW-SD, red cell distribution width.
Number of subjects 21 days after cobalt administration: cobalt group: n = 12, control group n = 5. Significance of differences from baseline (post-hoc tests): *, **, ***p < 0.05, 0.01,
0.001; vs. control group: #p < 0.05.
Because the highest urine Co2+ concentrations were found
at the end of the administration period, which also exceeded
those values measured after a single or 5-day application of the
identical Co2+ dosage, we may assume that Co2+ accumulates in
body fluids, which may lead to a stronger erythropoietic response
than expected from short-term administration. After cessation
of the administration, urine Co2+ concentration dropped by
approx. 80% within 2 days, which is consistent with the
elimination half-life of Co2+ after low-dose oral ingestion being
between 4 and 12 h (Ayala-Fierro et al., 1999; Tvermoes et al.,
2013). Nevertheless, compared to baseline, urine [Co2+] was
still elevated 2 weeks after cessation, which has implications
for establishing threshold limits to combat doping. In a pilot-
study, Krug et al. (Krug et al., 2014) calculated 14 ng/ml as a
tentative reference limit for urine Co2+ concentration, which was
determined by multiplying the reference population (n = 100
subjects) standard deviation by four. In this study, all participants
except one individual exceeded this threshold 1 week after
cessation (mean = 43.1 ± 47.1 ng/ml), and some individuals
exceeded it even after 2 or 3 weeks. Therefore, using the reference
limit mentioned above, it should be possible to detect cheating
athletes during doping and for at least 2 weeks after cessation of
Co2+ ingestion.
Erythropoietic Effect of Co2+
Administration
Co2+ mimics the effects of hypoxic exposure by stabilizing
the HIF 1α and 2α subunits and stimulating endogenous
erythropoietin synthesis (Jelkmann, 2012). According
to Jelkmann it was formerly thought that Co2+ could
replace the Fe2+ in the HIF-α prolyl hydroxylase.
Actual data indicate that Co2+ may bind to HIF 1α
and 2α preventing the interaction with the von-Hippel-
Landau tumor suppressor protein (pVHL) (Jelkmann,
2012).
In our recent study (Hoffmeister et al., 2018), we
demonstrated that a 5-day Co2+ administration of 10 mg/day
clearly passes the erythropoietic threshold, as indicated by
increased plasma [EPO], a higher percentage of IRF, and
decreased plasma ferritin concentration. Smaller dosages as 0.45
mg/day for 2 weeks (Tvermoes et al., 2013) and 1 mg/day for 90
days did not show any effect (Tvermoes et al., 2014) but a Co2+
application of 5 mg/day for 5 days showed a tendency toward
erythropoietic stimulation (Hoffmeister et al., 2018). The current
protocol indicated that the Co2+ administration of 5 mg/day
for 3 weeks produced clear erythropoietic stimulation, resulting
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FIGURE 3 | Changes in VO2max immediately and 1 week after the 3-week cobalt application period.
TABLE 4 | Performance data after a 3-week low dose Co2+ administration.
Baseline End of Co2+ administration One week after Co2+ administration
VO2max (ml/kg/min) Cobalt 52.6 ± 6.6 53.1 ± 6.8 52.8 ± 7.4
Placebo 52.0 ± 4.8 52.6 ± 5.9 53.1 ± 5.0
VO2max (l/min) Cobalt 3.90 ± 0.50 3.93 ± 0.47 3.90 ± 0.47
Placebo 4.03 ± 0.43 4.06 ± 0.54 4.15 ± 0.47
Peak power (Watts) Cobalt 305 ± 36 312 ± 35 315 ± 33
Placebo 322 ± 28 328 ± 30 328 ± 28
Time until exhaustion (mm:ss) Cobalt 18 :16 ± 2 : 06 18 : 37 ± 2 : 09 18 : 51 ± 2 :00
Placebo 18 :32 ± 1 : 43 18 : 51 ± 1 : 38 18 : 58 ± 1 :44
HR-Peak (bpm) Cobalt 186 ± 7 187 ± 6 189 ± 6
Placebo 185 ± 7 184 ± 6 185 ± 5
Lactate-Peak (mmol/l) Cobalt 11.6 ± 2.4 11.8 ± 2.0 12.0 ± 1.6
Placebo 11.4 ± 1.7 12.0 ± 1.3 12.1 ± 2.0
Power at 2 mmol/l lactate (Watts) Cobalt 143 ± 40 148 ± 37 154 ± 4.1
Placebo 162 ± 25 155 ± 16 154 ± 27
Power at 4 mmol/l lactate (Watts) Cobalt 212 ± 40 215 ± 36 219 ± 37
Placebo 222 ± 18 222 ± 22 218 ± 24
Presented are means ± standard deviations (SD).
in a 2% increase in Hbmass, which is similar to what has been
observed during hypoxic training camps lasting 200 h at an
altitude of∼2,000m (Garvican-Lewis et al., 2016).
To our knowledge, there have been no reports on [EPO]
following long-term Co2+ application making comparison of
our results to those in the literature difficult. In hypoxia, [EPO]
increases within 2 days and decreases within a few days to almost
baseline values (Wehrlin et al., 2006; Wachsmuth et al., 2013). It
is possible that a similar time course occurred in our study but we
did not make measurements of [EPO] during the first few days of
CoSupp. These measurements were not made since they would
require additional blood sampling which might have confounded
the interpretation of the erythropoietic stimulus.
The drop in ferritin in both the treatment and the placebo
groups was unexpected but might be due to the amount of
blood lost as result of the blood sampling required as part of the
experimental protocol. A total of 108ml of blood was required for
the analysis of blood parameters which may have altered the iron
status of both groups (Wachsmuth et al., 2015). This highlights
the need for experimental protocols where Hbmass is the key
dependent variable to consider the confounding factor of blood
sampling on this parameter.
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Performance Data
Although suppliers of nutritional supplements claim enhanced
endurance performance from Co2+ supplementation, this
hypothesis has not been verified in the scientific literature. In
a meta-analysis of 145 elite athletes, Saunders et al. (Saunders
et al., 2013) found a 3% increase in Hbmass and VO2max after
hypoxic exposure (“live high–train high” and “live high–train
low” protocols). The correlation between these changes was,
however, weak, and it explained less than one-sixth of the
variation, indicating that, apart from increased Hbmass, other
factors must also be important in causing the elevated VO2max
after altitude training (Saunders et al., 2013). In this study, we
found a close relationship between baseline Hbmass and VO2max
(r = 0.775, y = 3.3x + 1,121). The slope of the regression line
of 3.3 indicates that a change in Hbmass by 1 gram results in a
change of VO2max by 3.3 ml/min, which agrees closely with other
data in the literature (4 ml/min) (Schmidt and Prommer, 2010).
The change in Hbmass of ∼20 g in this study should result
in an increase in VO2max of ∼60 ml/min, corresponding to
1.5%. Such small differences, however, are very difficult to
detect with the commonly used spirometry systems; also, in our
laboratory, the methodological noise (typical error) for VO2max
determination using incremental cycle ergometer tests is 2.5%.
In addition, there is probably a variability in individual response
to the cobalt absorption, cobalt clearance, and interference with
HIFα as well as the dependency of VO2max on Hbmass. This is
supported by the tendency for significant relationship (r = 0.40,
p = 0.1) for changes in Hbmass and changes in VO2max. Also
the tendencies for increased power at lactate concentrations of 2
mmol/l and 4mmol/l (Table 4) hint to a performancemodulating
effect of cobalt.
CONCLUSION
We found that 5 mg/day Co2+ administration for 3 weeks
exceeds the erythropoietic threshold in young leisure-trained
men, leading to increased Hbmass and a tendency to improved
endurance performance. The urine Co2+ concentration greatly
exceeded the baseline values during the administration period,
and the elevated concentration lasted for at least 1 week after
cessation. Concerning the anti-doping fight, it seems to be
feasible to establish upper threshold limits for urine cobalt
concentrations.
AUTHOR CONTRIBUTIONS
TH, DS, MT, WB, and WS conceived the study. TH, DS, NW,
OK, HG, WB, and WS contributed to data collection, with TH,
WB, andWS performing all statistical analyses. TH,WB, andWS
drafted the manuscript, to which DS, NW, OK, HG, andMT then
contributed. All authors read and approved the final version of
the manuscript. TH, DS, NW, OK, HG, MT, WB, and WS agree
to be accountable for all aspects of the work in ensuring that
questions related to the accuracy or integrity of any part of the
work are appropriately investigated and resolved.
FUNDING
This project has been carried out with the support of The World
Anti-Doping Agency (Grant/Award Number: 13D21DS). This
publication was funded by the German Research Foundation
(DFG) and the University of Bayreuth in the funding program
Open Access Publishing.
REFERENCES
Ayala-Fierro, F., Firriolo, J. M., and Carter, D. E. (1999). Disposition, toxicity, and
intestinal absorption of cobaltous chloride in male Fischer 344 rats. J. Toxicol.
Environ. Health A 56, 571–591. doi: 10.1080/009841099157908
Bradberry, S., Sabatta, M., and Vale, J. (1989). Cobalt Chloride. Available online
at: http://www.inchem.org/documents/ukpids/ukpids/ukpid50.htm (Accessed
November 24, 2017).
Ebert, B., and Jelkmann, W. (2014). Intolerability of cobalt salt as erythropoietic
agent. Drug Test.Anal. 6, 185–189. doi: 10.1002/dta.1528
Finley, B. L., Monnot, A. D., Paustenbach, D. J., and Gaffney, S. H. (2012).
Derivation of a chronic oral reference dose for cobalt. Regul. Toxicol.
Pharmacol. 64, 491–503. doi: 10.1016/j.yrtph.2012.08.022
Garvican-Lewis, L. A., Sharpe, K., and Gore, C. J. (2016). Time for a
new metric for hypoxic dose? J. Appl. Physiol. (1985) 121, 352–355.
doi: 10.1152/japplphysiol.00579.2015
Hoffmeister, T., Schwenke, D., Krug, O., Wachsmth, N., Thevis, M., Byrnes, W.
C., et al. (2018). Erythropoietic effects of low-dose cobalt application.Drug Test
Anal. doi: 10.1002/dta.2478. [Epub ahead of print].
Jelkmann, W. (2012). The disparate roles of cobalt in erythropoiesis, and doping
relevance. Open J. Hematol. 3–6, doi: 10.13055/ojhmt_3_1_6.121211
Krug, O., Kutscher, D., Piper, T., Geyer, H., Schanzer, W., and Thevis, M.
(2014). Quantifying cobalt in doping control urine samples–a pilot study. Drug
Test.Anal. 6, 1186–1190. doi: 10.1002/dta.1694
Lippi, G., Franchini, M., and Guidi, G. C. (2005). Cobalt chloride administration
in athletes: a new perspective in blood doping? Br. J. Sports Med. 39, 872–873.
doi: 10.1136/bjsm.2005.019232
Lippi, G., Franchini, M., and Guidi, G. C. (2006). Blood doping by cobalt.
Should we measure cobalt in athletes? J. Occup. Med. Toxicol. 1:18.
doi: 10.1186/1745-6673-1-18
Prommer, N., and Schmidt, W. (2007). Loss of CO from the intravascular bed and
its impact on the optimised CO-rebreathing method. Eur. J. Appl. Physiol. 100,
383–391. doi: 10.1007/s00421-007-0439-2
Saunders, P. U., Garvican-Lewis, L. A., Schmidt, W. F., and Gore, C. J. (2013).
Relationship between changes in haemoglobin mass and maximal oxygen
uptake after hypoxic exposure. Br. J. Sports Med. 47(Suppl. 1), i26–i30.
doi: 10.1136/bjsports-2013-092841
Schmidt, W., and Prommer, N. (2005). The optimised CO-rebreathing method: a
new tool to determine total haemoglobin mass routinely. Eur. J. Appl. Physiol.
95, 486–495. doi: 10.1007/s00421-005-0050-3
Schmidt, W., and Prommer, N. (2010). Impact of alterations in total
hemoglobin mass on VO2max. Exerc. Sport Sci. Rev. 38, 68–75.
doi: 10.1097/JES.0b013e3181d4957a
Sottas, P. E., Robinson, N., Fischetto, G., Dolle, G., Alonso, J. M., and Saugy, M.
(2011). Prevalence of blood doping in samples collected from elite track and
field athletes. Clin. Chem. 57, 762–769. doi: 10.1373/clinchem.2010.156067
Thevis, M., Krug, O., Piper, T., Geyer, H., and Schanzer, W. (2016). Solutions
advertised as erythropoiesis-stimulating products were found to contain
undeclared cobalt and nickel species. Int. J. Sports Med. 37, 82–84.
doi: 10.1055/s-0035-1569350
Tvermoes, B. E., Finley, B. L., Unice, K. M., Otani, J. M., Paustenbach, D. J., and
Galbraith, D. A. (2013). Cobalt whole blood concentrations in healthy adult
male volunteers following two-weeks of ingesting a cobalt supplement. Food
Chem. Toxicol. 53, 432–439. doi: 10.1016/j.fct.2012.11.033
Frontiers in Physiology | www.frontiersin.org 8 September 2018 | Volume 9 | Article 1289
Hoffmeister et al. Low-Dose Cobalt and Hemoglobin Mass
Tvermoes, B. E., Unice, K. M., Paustenbach, D. J., Finley, B. L., Otani, J. M.,
and Galbraith, D. A. (2014). Effects and blood concentrations of cobalt after
ingestion of 1 mg/d by human volunteers for 90 d. Am. J. Clin. Nutr. 99,
632–646. doi: 10.3945/ajcn.113.071449
Wachsmuth, N. B., Aigner, T., Volzke, C., Zapf, J., and Schmidt, W. F. (2015).
Monitoring recovery from iron deficiency using total hemoglobin mass. Med.
Sci. Sports Exerc. 47, 419–427. doi: 10.1249/MSS.0000000000000420
Wachsmuth, N. B., Volzke, C., Prommer, N., Schmidt-Trucksass, A., Frese,
F., and Spahl, O., et al. (2013). The effects of classic altitude training
on hemoglobin mass in swimmers. Eur. J. Appl. Physiol. 113, 1199–1211.
doi: 10.1007/s00421-012-2536-0
WADA (2016). Guidelines Blood Sample Collection. Available online at: https://
wada-main-prod.s3.amazonaws.com/resources/files/guidelines_blood_
sample_collection_v5_sept_2016.pdf (Accessed November 24, 2017).
WADA (2017). List of Prohibited Substances and Methods. Available online
at: https://www.wada-ama.org/sites/default/files/prohibited_list_2018_en.pdf
(Accessed September 04, 2017).
Wehrlin, J. P., Zuest, P., Hallén, J., and Marti, B. (2006). Live high-train low for 24
days increases hemoglobinmass and red cell volume in elite endurance athletes.
J. Appl. Physiol. 100, 1938–1945. doi: 10.1152/japplphysiol.01284.2005
Wintermantel, J., Wachsmth, N., and Schmidt, W. (2016). Doping cases among
elite athletes from 2000 to 2013. Deut.Zeitschrift f.Sportmedizin. 67, 263–269.
doi: 10.5960/dzsm.2016.258
Conflict of Interest Statement: WS is a managing partner of the company Blood
tec GmbH, but he is unaware of any direct or indirect conflict of interest with the
contents of this paper.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be constructed as a potential
conflict of interest.
Copyright © 2018 Hoffmeister, Schwenke, Krug, Wachsmuth, Geyer, Thevis,
Byrnes and Schmidt. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s)
and the copyright owner(s) are credited and that the original publication in
this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Physiology | www.frontiersin.org 9 September 2018 | Volume 9 | Article 1289
